Company Overview of Alios BioPharma, Inc.
Alios BioPharma, Inc., a clinical stage biotechnology company, develops antiviral therapies for the treatment of respiratory diseases. It develops AL-8176, an anti- respiratory syncytial virus (RSV) nucleoside analog for the treatment of RSV; VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company also engages in developing a nucleoside library for identifying therapeutics for treatment of various viral infections, such as RSV, picornavirus (rhinovirus), influenza, norovirus, and other viral diseases. Alios BioPharma, Inc. was incorporated in 2006 and is based in South San Francisco, California.
260 East Grand Avenue
South San Francisco, CA 94080
Founded in 2006
Key Executives for Alios BioPharma, Inc.
Founder and Chief Scientific Officer
Founder and Chief Business Officer
Senior Director of Operations and Project Management
Vice President of Drug Discovery
Compensation as of Fiscal Year 2013.
Alios BioPharma, Inc. Key Developments
Alios BioPharma, Inc. Reports Significant Progress with its Clinical Program for AL-8176, its Nucleoside Analog for the Treatment of Respiratory Syncytial Virus
Jan 13 14
Alios BioPharma, Inc. announced it is initiating a Phase 2a study designed to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of AL-8176 against respiratory syncytial virus (RSV) infection in a virus challenge model. This clinical trial follows the successful completion of a Phase I clinical trial for AL-8176, its orally delivered, structurally novel anti-RSV nucleoside analog being developed as a treatment for RSV in infants. Top-Line Results of AL-8176 Phase 1 Study: The safety and PK of AL-8176 was evaluated as single and multiple ascending oral doses in a Phase 1 study in adult healthy volunteers (Study AL-8176-501). A total of 100 healthy volunteers were enrolled and received single doses and multiple doses of AL-8176 or placebo for up to 14 days. AL-8176 was well tolerated in this study, with no serious adverse events being reported and no adverse events leading to discontinuation. About the AL-8176 Phase 2a Study: AL-8176-502 is a randomized, double-blind, placebo-controlled Phase 2a study designed to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of AL-8176 against RSV infection in a virus challenge model. Approximately 66 healthy volunteers will be enrolled and inoculated with RSV, and subsequently given multiple doses of AL-8176 or placebo for five days. This study is expected to be completed by mid-year 2014. The human challenge model has been successfully used to evaluate proof-of-concept for antiviral agents and enable more rapid advancement of investigational agents to Phase 2b and beyond. About AL-8176: AL-8176 is a nucleoside analog which is being developed by Alios BioPharma as an orally administered antiviral therapy for the treatment of infants infected with RSV. AL-8176 is designed to inhibit the replication of the RSV by acting on the viral polymerase. In vitro studies of the compound showed potent and highly selective inhibition of both RSV laboratory-adapted A and B strains as well as a range of diverse clinical isolates. In addition, administration of AL-8176 resulted in potent multi-log suppression of RSV in an in vivo preclinical model. About RSV: RSV is the leading cause of lower respiratory disease in infants (Nair et al. 2010). In 2005, an estimated 33.8 million episodes of RSV infection occurred worldwide in infants and young children with most of these occurring in otherwise healthy full term infants. Of these, at least 3.4 million severe cases of lower respiratory tract infection (LRI) required hospitalization, and an estimated 66,000 to 199,000 deaths occurred, mostly in the developing world (Nair et al. 2010). In the United States, RSV infects at least 68% of the birth cohort each year (Shay et al. 1999, Glezen et al. 1986). By the second year in life, most children have been exposed to RSV (Hall et al. 2001). Results of a prospective, population-based inpatient and outpatient surveillance for acute respiratory infections in children younger than 5 years suggest that approximately 2.1 million children under 5 in the United States require medical attention for RSV each year.
Alios BioPharma, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013
Aug 9 13
Alios BioPharma, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 . Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.
Alios BioPharma, Inc. Initiates Phase 1 Clinical Trial for Respiratory Syncytial Virus Infection
May 30 13
Alios BioPharma, Inc. announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection. It is the only known nucleoside analog currently in clinical development for the treatment of RSV. ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV in preclinical studies and represents an important step forward in the development of more effective treatments for this serious and often life threatening disease. The randomized, double-blind, placebo-controlled, Phase 1 study of orally administered ALS-8176 will evaluate safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses in healthy volunteers. The trial will assess several dose levels in up to 90 healthy adults. ALS-8176 was discovered following the optimization of screening hits obtained through testing the Alios proprietary nucleoside analog library against replicating RSV in cell culture. The compound acts by blocking replication through a classic chain-termination mechanism and inhibits all RSV strains tested. Due to their high barrier to viral resistance, nucleoside analogs have become the backbone of antiviral therapy in many clinical settings including the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpes simplex virus (HSV). More recently, emerging data suggest the pivotal role nucleoside analogs will play in the future treatment of chronic hepatitis C (HCV).
Similar Private Companies By Industry
Recent Private Companies Transactions
April 7, 2014